Carbetocin Versus Oxytocin and Hemodynamic Effects
Information source: Rikshospitalet HF
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pregnancy, Anesthesia
Intervention: carbetocin 100 µg (Drug); oxytocin 5 u (Drug); placebo (NaCl) (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Rikshospitalet HF Official(s) and/or principal investigator(s):
Leiv Arne Rosseland, MD PhD, Principal Investigator, Affiliation: Oslo University Hospital - Rikshospitalet
Overall contact:
Leiv Arne Rosseland, MD PhD, Phone: 23073700, Ext: 47, Email: l.a.rosseland@medisin.uio.no
Summary
A randomized double-blind trial of oxytocin 5 u, carbetocin 100 µg and placebo with
hemodynamic response as a primary outcome measure.
Clinical Details
Official title: Hemodynamiske Effekter av Carbetocin 100 µg, Oxytocin 5 IE og Placebo Hos Kvinner Som gjennomgår Keisersnitt i spinalbedøvelse
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Primary outcome: Cardiac output
Secondary outcome: Blood pressurePeripheral vascular resistance Bleeding
Detailed description:
Healthy pregnant women sheduled for elective cesarean section. Invasive hemodynmaic
monitoring with LiDCO Plus.
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Healthy pregnant women for planned cesarean section
Exclusion Criteria:
- Bleeding disorders
- Placenta disorders
Locations and Contacts
Leiv Arne Rosseland, MD PhD, Phone: 23073700, Ext: 47, Email: l.a.rosseland@medisin.uio.no
Division of Anaesthesia and Intensive Care Medicine, Oslo University Hospital - Rikshospitalet, Oslo 0027, Norway
Additional Information
Starting date: October 2009
Ending date: June 2011
Last updated: September 16, 2009
|
